IBDEI0BY ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5665,0)
 ;;=203.01^^41^488^105
 ;;^UTILITY(U,$J,358.3,5665,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5665,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,5665,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,5665,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,5666,0)
 ;;=238.6^^41^488^108
 ;;^UTILITY(U,$J,358.3,5666,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5666,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,5666,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,5666,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,5667,0)
 ;;=205.00^^41^488^4
 ;;^UTILITY(U,$J,358.3,5667,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5667,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,5667,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,5667,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,5668,0)
 ;;=205.01^^41^488^6
 ;;^UTILITY(U,$J,358.3,5668,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5668,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,5668,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,5668,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,5669,0)
 ;;=205.10^^41^488^19
 ;;^UTILITY(U,$J,358.3,5669,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5669,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,5669,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,5669,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,5670,0)
 ;;=205.11^^41^488^21
 ;;^UTILITY(U,$J,358.3,5670,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5670,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,5670,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,5670,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,5671,0)
 ;;=289.0^^41^488^55
 ;;^UTILITY(U,$J,358.3,5671,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5671,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,5671,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,5671,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,5672,0)
 ;;=238.4^^41^488^109
 ;;^UTILITY(U,$J,358.3,5672,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5672,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,5672,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,5672,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,5673,0)
 ;;=V58.61^^41^488^126
 ;;^UTILITY(U,$J,358.3,5673,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5673,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,5673,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,5673,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,5674,0)
 ;;=282.49^^41^488^117
 ;;^UTILITY(U,$J,358.3,5674,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5674,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,5674,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,5674,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,5675,0)
 ;;=289.89^^41^488^15
 ;;^UTILITY(U,$J,358.3,5675,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5675,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,5675,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,5675,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,5676,0)
 ;;=238.79^^41^488^88
 ;;^UTILITY(U,$J,358.3,5676,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5676,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,5676,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,5676,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,5677,0)
 ;;=287.30^^41^488^110
 ;;^UTILITY(U,$J,358.3,5677,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5677,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,5677,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,5677,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,5678,0)
 ;;=288.09^^41^488^8
 ;;^UTILITY(U,$J,358.3,5678,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5678,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,5678,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,5678,2)
 ;;=^334042
